We are seeking postdoctoral neuropharmacologist to study functionally selective small molecule therapeutics targeting the CNS Adrenergic receptors.
The failure of experimental therapeutics for Alzheimer’s disease (AD) in clinical studies emphasizes the need for novel therapeutic targets with new mechanisms of action and chemical ligands that can safely modulate these targets. To accomplish this, our laboratory has focused on the noradrenergic (NA) system, which is a key system that regulates many physiological functions and defense mechanisms. The adrenergic receptor (ADRs) is a promising and well validated therapeutic target tightly involved in the cognitive deficits and pathological features associated with AD. Novel small molecule modulators of ADRs, engineered to be highly brain permeable, will have tremendous value both as pharmacological tools to dissect the roles of ADRs in CNS and as potential lead molecules for further preclinical development. Although there is a clear clinical need for a CNS-permeable ADRs ligand, no highly brain permeable ADR ligand exists. We are developing novel, potent, CNS-active, ADR ligands with functional selectivity.
The aim of this project is to design, identify, and develop novel ADR ligands using interdisciplinary approach. The project will involve collaborating with medicinal chemists involved in synthesis and design of novel molecules, understanding structure activity relationship around our target, and profiling pharmacological properties of the novel molecules.
The postdoctoral scientists/students enrolled in this program will interact and collaborate heavily with medicinal chemists, translational neurobiologists, and neuropharmacologists in the laboratory studying diverse CNS disorders using pharmacological, mechanistic and behavioral tools.
Applicants should have PhD degree in neurobiology, neuropharmacology, or related science.
Good working knowledge in molecular pharmacology, molecular biology, pathology and biochemistry.
Proficiency with experimental approaches common to the filed (e.g. mammalian cell culture, qRT-PCR, ELISA, Western blot, immunofluorescence staining, sectioning and microscopy, etc).
Demonstrated ability to independently design and execute experiments, interpret data and identify appropriate follow-up strategies.
As part of the Stanford Neurosciences Institute, BFNL provides a preclinical discovery platform for CNS target validation in preclinical in vivo and in vitro models. Our well validated neurobehavioral assessment tools in CNS disease models provide a unique platform for the screening and profiling of experimental therapeutics and genetic rodent models. We aim to accelerate the progress in both fun...damental and applied studies of nervous system function. We collaborate with academic laboratories, non-profit foundations, and biopharmaceutical companies worldwide to support the understanding of human CNS disorders and develop therapeutic interventions.